Evidence map›Paper›PMID 39950272›Full record

ReviewCurrent pharmaceutical biotechnology2026

Application of Probiotics and Postbiotics in Neurological Disorders.

Darya Mohammadpour, Afsoon Asadollahi, Mahdi Asghari Ozma, Bahareh Mehramuz, Khudaverdi Ganbarov, Hossein Samadi Kafil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Darya MohammadpourStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Afsoon AsadollahiDepartment of Maxillofacial Medicine, Faculty of Dentistry, Urmia University of Medical Sciences, Urmia, Iran.
Mahdi Asghari OzmaStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Bahareh MehramuzResearch Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
Khudaverdi GanbarovResearch Laboratory of Microbiology and Virology, Baku State University, Baku, Azerbaijan.
Hossein Samadi KafilDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

Tabriz University of Medical Sciences, Tabriz, Iran 74041
6 · The paper itself

Abstract

Neurological illnesses encompass a broad spectrum of conditions that affect the brain, spine, and nerves, often impairing daily functioning. The global prevalence of these illnesses is rising, posing significant health challenges. This study investigates the beneficial effects of probiotics and postbiotics in managing various neurological disorders, providing a comprehensive analysis of their use in treating these conditions. The article explores innovative, holistic approaches to neurological care, emphasizing patient-centered therapeutic interventions. Compelling evidence suggests that probiotics and postbiotics positively impact several neurological diseases. Specifically, the findings indicate that these treatments can modulate the gut-brain axis, reduce neuroinflammation, and enhance neuronal protection. The study highlights the potential of specific bacteria and their byproducts to ameliorate neurological disorders. Despite promising results, the current data underscore the challenges in future research on the therapeutic benefits of probiotics and postbiotics for neurological illnesses and underscores the critical role of the gut-brain connection and the microbiome in maintaining neurological health. It also examines the safety and feasibility of using probiotics and postbiotics as adjunct therapies, delving into the mechanisms underlying their beneficial effects. Probiotics and postbiotics demonstrate a capacity to enhance the regenerative potential of the human brain, and recent evaluations provide additional evidence supporting their efficacy and safety. However, further rigorous clinical trials are necessary to validate these findings and establish the most effective therapeutic strategies for treating neurological disorders.

Indexed as

Nervous System DiseasesProbioticsAnimalsBrainGastrointestinal MicrobiomeHumansgut-brain axisgut microbiotaneurological disorderspostbioticsProbioticstherapeutic interventions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.